CMS has abandoned its plan to give private plans more leverage in the “protected” drug classes in Part D. It will probably be a long time before anyone tries to change the protected classes again.
At this point, it seems safe to say that the “Protected Classes” in the US Medicare Part D program have achieved the political status of the third rail in a subway system: do not touch them if you don’t want to get a shock.
Make no mistake: the final rule published by the Centers for Medicare & Medicaid Services May 16 and bearing the...
Excluding information about acquisition costs could indicate a manufacturer had no R&D spending to recoup for a drug selected for Medicare price negotiation, which could cause CMS to inappropriately lower its price offer.
Hospitals urged HRSA to require that manufacturers cover all costs associated with their participation, while pharma argued for a more narrowly defined responsibility, as model implementation moves forward.
The US Supreme Court ruled the Affordable Care Act’s preventive care coverage mandate is constitutional, but HHS Secretary Robert F. Kennedy Jr. may have gained more power over what is classified as preventive care.
Heavy lobbying produced relief for orphan drugs in President Trump's budget reconciliation law and the cost of the changes to Medicare now is becoming clearer.
The US Supreme Court ruled the Affordable Care Act’s preventive care coverage mandate is constitutional, but HHS Secretary Robert F. Kennedy Jr. may have gained more power over what is classified as preventive care.
Heavy lobbying produced relief for orphan drugs in President Trump's budget reconciliation law and the cost of the changes to Medicare now is becoming clearer.
The Australian government says it is taking “immediate actions” to overhaul its health technology assessment system. This will include updating guidelines around using the lowest cost comparator drug in HTAs, a practice that industry has long opposed.
